BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25225010)

  • 1. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
    Stene GB; Helbostad JL; Amundsen T; Sørhaug S; Hjelde H; Kaasa S; Grønberg BH
    Acta Oncol; 2015 Mar; 54(3):340-8. PubMed ID: 25225010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.
    Sjøblom B; Benth JŠ; Grønberg BH; Baracos VE; Sawyer MB; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
    Clin Lung Cancer; 2017 Mar; 18(2):e129-e136. PubMed ID: 27825639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Benth JŠ; Baracos VE; Fløtten Ø; Hjermstad MJ; Aass N; Jordhøy M
    Lung Cancer; 2015 Oct; 90(1):85-91. PubMed ID: 26198373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
    von Plessen C; Bergman B; Andresen O; Bremnes RM; Sundstrom S; Gilleryd M; Stephens R; Vilsvik J; Aasebo U; Sorenson S
    Br J Cancer; 2006 Oct; 95(8):966-73. PubMed ID: 17047644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
    Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
    Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
    Quoix E; Ducoloné A; Mennecier B; Fraisse P
    Presse Med; 2011 Apr; 40(4 Pt 1):420-6. PubMed ID: 21388776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
    Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK
    Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
    Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
    Najjar F; Al-Massarani G; Banat I; Alammar M
    Int J Biol Markers; 2015 Nov; 30(4):e374-81. PubMed ID: 26109363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
    Quoix E; Zalcman G; Oster JP; Westeel V; Pichon E; Lavolé A; Dauba J; Debieuvre D; Souquet PJ; Bigay-Game L; Dansin E; Poudenx M; Molinier O; Vaylet F; Moro-Sibilot D; Herman D; Bennouna J; Tredaniel J; Ducoloné A; Lebitasy MP; Baudrin L; Laporte S; Milleron B;
    Lancet; 2011 Sep; 378(9796):1079-88. PubMed ID: 21831418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J; Leaw SJ; Xu Y; Zheng D
    Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
    Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
    Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; De Cataldis G; Cioffi R; Maiorino L; Micillo E; Lorusso V; Di Rienzo G; Filippelli G; Lamberti A; Natale M; Bilancia D; Nicolella G; Di Nota A; Comella G
    J Clin Oncol; 2000 Apr; 18(7):1451-7. PubMed ID: 10735892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Gray JR; Morrissey LH; Kalman LA; Hon JK; Greco FA
    J Clin Oncol; 2002 Jul; 20(13):2937-42. PubMed ID: 12089222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.